Found: 183
Select item for more details and to access through your institution.
Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
- Published in:
- 2018
- By:
- Publication type:
- journal article
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.
- Published in:
- Cancer Biology & Medicine, 2024, v. 21, n. 10, p. 934, doi. 10.20892/j.issn.2095-3941.2024.0204
- By:
- Publication type:
- Article
PHOEBE Update Confirms Overall Survival Benefit of Pyrotinib in HER2-Positive Metastatic Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2022, p. 15
- By:
- Publication type:
- Article
Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 3, p. 457, doi. 10.3390/jpm13030457
- By:
- Publication type:
- Article
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 2, p. 190, doi. 10.3390/jpm13020190
- By:
- Publication type:
- Article
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 2, p. N.PAG, doi. 10.3390/jpm12020323
- By:
- Publication type:
- Article
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials.
- Published in:
- Frontiers of Medicine, 2021, v. 15, n. 2, p. 208, doi. 10.1007/s11684-020-0795-4
- By:
- Publication type:
- Article
Progress in systemic therapy for triple-negative breast cancer.
- Published in:
- Frontiers of Medicine, 2021, v. 15, n. 1, p. 1, doi. 10.1007/s11684-020-0741-5
- By:
- Publication type:
- Article
Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 3, p. 345, doi. 10.1093/jjco/hyaa216
- By:
- Publication type:
- Article
Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
- Published in:
- Journal of Oncology, 2020, p. 1, doi. 10.1155/2020/8880727
- By:
- Publication type:
- Article
Anticancer drug R&D landscape in China.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.
- Published in:
- BMC Geriatrics, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12877-023-03886-2
- By:
- Publication type:
- Article
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 197, n. 3, p. 503, doi. 10.1007/s10549-022-06775-1
- By:
- Publication type:
- Article
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 197, n. 3, p. 489, doi. 10.1007/s10549-022-06785-z
- By:
- Publication type:
- Article
Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 193, n. 2, p. 381, doi. 10.1007/s10549-022-06559-7
- By:
- Publication type:
- Article
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 191, n. 1, p. 97, doi. 10.1007/s10549-021-06401-6
- By:
- Publication type:
- Article
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 2, p. 441, doi. 10.1007/s10549-021-06216-5
- By:
- Publication type:
- Article
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 182, n. 3, p. 689, doi. 10.1007/s10549-020-05728-w
- By:
- Publication type:
- Article
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 182, n. 1, p. 67, doi. 10.1007/s10549-020-05648-9
- By:
- Publication type:
- Article
Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 173, n. 2, p. 487, doi. 10.1007/s10549-018-5047-9
- By:
- Publication type:
- Article
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 171, n. 3, p. 535, doi. 10.1007/s10549-018-4867-y
- By:
- Publication type:
- Article
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.
- Published in:
- Signal Transduction & Targeted Therapy, 2019, v. 4, n. 1, p. N.PAG, doi. 10.1038/s41392-019-0069-2
- By:
- Publication type:
- Article
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241275422
- By:
- Publication type:
- Article
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241273026
- By:
- Publication type:
- Article
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231204856
- By:
- Publication type:
- Article
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, v. 15, p. 1, doi. 10.1177/17588359231178125
- By:
- Publication type:
- Article
Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 4, p. 1025, doi. 10.1245/s10434-019-08092-2
- By:
- Publication type:
- Article
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: A retrospective comparison of East Asian and global studies.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2014, v. 10, n. 4, p. 330, doi. 10.1111/ajco.12116
- By:
- Publication type:
- Article
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2010, v. 6, n. 4, p. 320, doi. 10.1111/j.1743-7563.2010.01323.x
- By:
- Publication type:
- Article
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 503, doi. 10.1007/s10637-023-01351-w
- By:
- Publication type:
- Article
The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.
- Published in:
- International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 707, doi. 10.1007/s10147-022-02115-x
- By:
- Publication type:
- Article
The emerging role of RNA N6-methyladenosine methylation in breast cancer.
- Published in:
- Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00295-8
- By:
- Publication type:
- Article
Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.
- Published in:
- Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00285-w
- By:
- Publication type:
- Article
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer.
- Published in:
- Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00271-2
- By:
- Publication type:
- Article
The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis.
- Published in:
- Scientific Reports, 2017, p. 42045, doi. 10.1038/srep42045
- By:
- Publication type:
- Article
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45160-y
- By:
- Publication type:
- Article
Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920925991
- By:
- Publication type:
- Article
Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0138908
- By:
- Publication type:
- Article
Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0136826
- By:
- Publication type:
- Article
Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0136268
- By:
- Publication type:
- Article
Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0128345
- By:
- Publication type:
- Article
Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0113574
- By:
- Publication type:
- Article
A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0112765
- By:
- Publication type:
- Article
Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
- Published in:
- PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0104870
- By:
- Publication type:
- Article
MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis.
- Published in:
- PLoS ONE, 2014, v. 9, n. 8, p. 1, doi. 10.1371/journal.pone.0103373
- By:
- Publication type:
- Article